Sana Biotechnology (SANA) Net Equity Issued and Repurchased (2020 - 2026)

Sana Biotechnology has reported Net Equity Issued and Repurchased for 5 years, with the latest figure at $17.0 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $17.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $46.1 million (down 74.53% YoY) and the FY2025 annual result came in at $126.4 million, down 30.16% from the prior year.
• Net Equity Issued and Repurchased slipped to $17.0 million in Q4 2025 per SANA's latest filing, from $28.6 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $152.3 million in Q2 2024 and troughed at -$29000.0 in Q3 2024.
• A 4-year average of $18.5 million and a median of $1.4 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased tumbled 115.1% in 2024, then soared 98720.69% in 2025.
• Over 4 years, Net Equity Issued and Repurchased stood at $1.2 million in 2022, then surged by 1935.56% to $24.1 million in 2023, then plunged by 100.12% to -$29000.0 in 2024, then jumped by 58720.69% to $17.0 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $17.0 million, $28.6 million, and $500000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.